Unknown

Dataset Information

0

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.


ABSTRACT: Background:We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9-14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15-25 years. Here, we report the results at study end (month 36 [M36]). Methods:Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or 12 months apart (2D_M0,12); women received 3 doses at months 0, 1, and 6 (3D_M0,1,6). Endpoints included noninferiority of HPV-16/18 antibodies for 2D_M0,6 versus 3D_M0,1,6; 2D_M0,12 versus 3D_M0,1,6; and 2D_M0,12 versus 2D_M0,6; and assessment of neutralizing antibodies, T cells, B cells, and safety. Results:At M36, the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for anti-HPV-16 and anti-HPV-18. All schedules elicited sustained immune responses up to M36. Conclusions:Both 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study conclusion at M36. The AS04-HPV-16/18 vaccine administered as a 2-dose schedule was immunogenic and well tolerated in young girls.

SUBMITTER: Huang LM 

PROVIDER: S-EPMC5853959 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9-14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15-25 years. Here, we report the results at study end (month 36 [M36]).<h4>Methods</h4>Girls were randomized 1:1 and received 2 vaccine doses either 6 months (  ...[more]

Similar Datasets

| S-EPMC2908791 | biostudies-literature
| S-EPMC4514190 | biostudies-literature
| S-EPMC3898269 | biostudies-literature
| S-EPMC3636781 | biostudies-literature
| S-EPMC4186032 | biostudies-literature
| S-EPMC4962738 | biostudies-literature
| S-EPMC6746471 | biostudies-literature
| S-EPMC4013406 | biostudies-literature
| S-EPMC6500548 | biostudies-literature
| S-EPMC4957434 | biostudies-literature